Literature DB >> 2239939

Adult and pediatric peritonitis rates in a home dialysis program: comparison of continuous ambulatory and continuous cycling peritoneal dialysis.

R L Howard1, J Millspaugh, I Teitelbaum.   

Abstract

We reviewed our 115-month experience with continuous ambulatory peritoneal dialysis (CAPD) and continuous cycling peritoneal dialysis (CCPD) in adult and pediatric patients to determine whether there is a difference in the incidence of peritonitis between patients performing CAPD or CCPD. Peritonitis rates were similar in patients performing CAPD or CCPD in both the adult and pediatric age groups. The overall CAPD peritonitis rate was significantly lower in adult patients when compared with pediatric patients. There was no difference in peritonitis rates for CCPD between adult and pediatric patients. When the data are divided into 3-year subgroups, the incidence of peritonitis is significantly lower in adult patients undergoing either CAPD or CCPD when compared with pediatric patients during the years 1986 to 1988. There is significant improvement over time in the incidence of peritonitis in both adult and pediatric patients performing CCPD; similarly, there is a trend toward improvement in patients performing CAPD. Staphylococcus species organisms remain the most common bacterial cause of peritonitis, except in pediatric patients under the age of 2 years or with nephrostomies, where gram-negative rod infections were more common. Peritonitis resulted in discontinuation of peritoneal dialysis in a greater number of adult patients. These results suggest that the number of catheter manipulations is not important in determining the incidence of peritonitis. Pediatric patients are more likely than adult patients to develop peritonitis with either CAPD or CCPD. Adult patients are more likely than pediatric patients to discontinue peritoneal dialysis secondary to peritonitis.

Entities:  

Mesh:

Year:  1990        PMID: 2239939     DOI: 10.1016/s0272-6386(12)80061-8

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  7 in total

1.  Relapsing peritonitis in children who undergo chronic peritoneal dialysis: a prospective study of the international pediatric peritonitis registry.

Authors:  Jerome C Lane; Bradley A Warady; Reinhard Feneberg; Nancy L Majkowski; Alan R Watson; Michel Fischbach; Hee Gyung Kang; Klaus E Bonzel; Eva Simkova; Constantinos J Stefanidis; Günter Klaus; Steven R Alexander; Mesiha Ekim; Ilmay Bilge; Franz Schaefer
Journal:  Clin J Am Soc Nephrol       Date:  2010-04-29       Impact factor: 8.237

Review 2.  Management of peritonitis in children receiving chronic peritoneal dialysis.

Authors:  Franz Schaefer
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

3.  Effect of rifampin on Staphylococcus aureus colonization in children on chronic peritoneal dialysis.

Authors:  C D Hanevold; M C Fisher; R Waltz; S Bartosh; H J Baluarte
Journal:  Pediatr Nephrol       Date:  1995-10       Impact factor: 3.714

4.  Intraperitoneal administration of recombinant human erythropoietin in children on continuous ambulatory peritoneal dialysis.

Authors:  R E Reddingius; C H Schröder; L A Monnens
Journal:  Eur J Pediatr       Date:  1992-07       Impact factor: 3.183

Review 5.  Continuous ambulatory peritoneal dialysis versus automated peritoneal dialysis for end-stage renal disease.

Authors:  K S Rabindranath; J Adams; T Z Ali; A M MacLeod; L Vale; J Cody; S A Wallace; C Daly
Journal:  Cochrane Database Syst Rev       Date:  2007-04-18

6.  Infectious and catheter-related complications in pediatric patients treated with peritoneal dialysis at a single institution.

Authors:  B Kuizon; T L Melocoton; M Holloway; S Ingles; E W Fonkalsrud; I B Salusky
Journal:  Pediatr Nephrol       Date:  1995       Impact factor: 3.714

Review 7.  Congenital nephrotic syndrome: is early aggressive treatment needed? Yes.

Authors:  Tuula Hölttä; Hannu Jalanko
Journal:  Pediatr Nephrol       Date:  2020-05-06       Impact factor: 3.714

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.